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23 The coexistence of aldosterone oversecretion and obstructive sleep apnea is frequently observed, 
24 especially in patients with resistant hypertension, obesity and metabolic syndrome. Since aldosterone 
25 excess and sleep apnea are both independently associated with an increased risk of cardiovascular 
26 disease, to investigate whether their coexistence might be attributed to common predisposing 
27 conditions, such as metabolic disorders, or to an actual pathophysiological interconnection appears 
28 of great importance. Fluid overload and metabolic abnormalities relating to aldosterone oversecretion 
29 may be implicated in obstructive sleep apnea development. Nocturnal intermittent hypoxia may in 
30 turn exacerbate renin-angiotensin-aldosterone system activity, thus leading to hyperaldosteronism. 
31 Furthermore, fat tissue excess and adipocyte secretory products might predispose to both sleep apnea 
32 and aldosterone oversecretion in subjects with obesity. Consistent with these evidences, obstructive 
33 sleep apnea frequently affects patients with primary aldosteronism. Conversely, whether primary 
34 aldosteronism is more prevalent in individuals affected by obstructive sleep apnea compared to the 
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45 Obstructive sleep apnea (OSA), aldosterone excess and resistant hypertension (RH) are common 
46 comorbidities, especially in patients affected by obesity[1]. The prevalence of OSA is high in patients 
47 affected by RH and even higher in individuals with hypertension refractory to medical therapy[2]. In 
48 patients with RH, oversecretion of aldosterone is a frequent finding and primary aldosteronism (PA) 
49 has a significantly higher prevalence compared with the general hypertensive population[3]. Patients 
50 with RH are significantly more likely to experience adverse cardiovascular outcomes, such as stroke, 
51 myocardial infarction, heart failure, renal failure and death, compared with subjects with nonresistant 
52 hypertension[4]. Studies performed in the last years suggest that PA is frequent in patients with 
53 OSA[5,6] and, on the basis of these evidences, the 2016 Endocrine Society Guideline recommends 
54 to screen for PA all patients with hypertension and OSA[7]. The impact of aldosterone excess and 
55 sleep apnea on the cardiovascular morbidity and mortality of patients with hypertension is of great 
56 importance, as well as the recognition of the interplay between these conditions. Previous studies 
57 hypothesized that a bidirectional relationship between aldosterone levels and OSA might be present 
58 in patients with RH and PA[8]. Nevertheless, whether the association between PA and OSA is 
59 accidental or pathophysiologically-based remains controversial.
60
61 Epidemiology
62 1.Primary aldosteronism 
63 PA is mostly sporadic, due to unilateral aldosterone-producing adenoma (APA) or bilateral 
64 hyperaldosteronism (BHA), and less frequently (1-6%) is a familiar condition[9]. Individuals with 
65 PA show an increased risk of stroke, coronary artery disease, heart failure, atrial fibrillation, left 
66 ventricular hypertrophy, kidney damage, diabetes and metabolic syndrome compared to patients with 
67 essential hypertension[10, 11]. The prevalence of PA rates between 5.9% in the general hypertensive 
68 population[12] and 11.2% in patients from referral centers[13], and progressively increases with 
69 hypertension severity[12]. 
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70 Two prospective studies suggested a high prevalence of aldosterone excess in patients with sleep 
71 disordered breathing (SDB). Calhoun et al. showed that autonomous aldosterone secretion was more 
72 frequently observed in patients with RH at high risk of OSA (36%) compared with low-risk patients 
73 (19%), defined according to the Berlin Questionnaire results[5]. However, OSA diagnosis was not 
74 confirmed by polysomnography and patients with aldosterone oversecretion did not underwent 
75 confirmatory testing for PA diagnosis. Di Murro et al. reported a 34% prevalence of PA in patients 
76 affected by hypertension and OSA[6]. Nonetheless, polysomnography was performed only in patients 
77 showing excessive daytime sleepiness, thus leading to diagnosis of OSA only in a selected subgroup 
78 of symptomatic individuals. Therefore, it cannot be excluded that PA prevalence among the overall 
79 symptomatic and asymptomatic OSA population would have been different. 
80 The recent multicenter multi-ethnic cross-sectional HYPNOS study, reported an 8.9% prevalence of 
81 PA in a population of 203 patients with OSA (102 Caucasians and 101 Chinese)[14], a figure that 
82 does not significantly differ from the 5.9-11.2% prevalence observed in the PATO and PAPY studies, 
83 respectively[12,13]. Moreover, a sub-analysis performed to identify PA prevalence in patients in 
84 whom OSA was the only indication to proceed to PA screening, showed that only 1/63 (1.5%) patients 
85 displayed confirmed PA. These results provocatively challenge the current Endocrine Society 
86 Guideline recommendation to screen for PA all patients affected by OSA and arterial hypertension, 
87 irrespective of hypertension severity and the presence of other risk factors.
88
89 2.Obstructive sleep apnea 
90 OSA is a chronic sleep disorder characterized by recurrent episodes of complete (apneas) or partial 
91 airflow cessation (hypopneas) due to obstruction of the upper respiratory tract, leading to intermittent 
92 hypoxia, hypercapnia and sleep arousals[15]. OSA is an independent risk factor for hypertension[16-
93 18] and cardiovascular disease [19,20], and a predictor of cardiovascular outcomes, including sudden 
94 cardiac death[21]. OSA is frequently diagnosed in patients with various cardiovascular comorbidities, 
95 such as stroke, end-stage chronic kidney disease, ischemic cardiomyopathy, heart failure, atrial 
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96 fibrillation and hypertrophic cardiomyopathy[15]. The prevalence of OSA in the overall adult 
97 population varies from 9% to 38%, ranging between 13% to 33% in men and 6% to 19% in 
98 women[22]. Advanced age is associated with an elevated prevalence of OSA, up to 90% for all stages 
99 in a cohort of elderly men[22,23]. OSA prevalence is high in patients with obesity or metabolic 
100 syndrome, ranging from 50% to 60%, and it is even higher in subjects with morbid obesity and 
101 diabetes[24]. The prevalence of OSA in patients with hypertension is reported to be 30% to 50%[25] 
102 and it has been assessed to be as high as 92%[26] for all stages and 70% for severe OSA[27] in 
103 patients with RH. A recent study displayed an even higher prevalence of moderate OSA (95.2%), 
104 severe OSA (64.3%) and OSA syndrome (52.4%) in patients with refractory hypertension[2].
105 Some studies showed that OSA is more frequent in patients with than in those without PA. In a 
106 retrospective cohort, OSA prevalence was significantly higher in subjects with autonomous 
107 aldosterone secretion (18%) compared with patients without it (9%)[28]. However, the lack of PA 
108 confirmatory testing and the identification of OSA patients using database records are the major 
109 limitations of this study. Indeed, the prevalence of OSA in both PA and non-PA hypertensive patients 
110 resulted even lower than the one observed in the general population[22]. In a prospective study, the 
111 reported OSA prevalence was 78.1% and 71.0% in patients affected by RH with and without PA, 
112 respectively, and OSA severity was shown to be higher in the former group[29]. In a recent study 
113 aimed at exploring the effects of PA treatment on OSA severity, a 79% prevalence of OSA was 
114 showed in patients with PA[30]. Nevertheless, it should be noted that the study cohort was selected 
115 by the presence of at least one risk factor for sleep apnea, such as male gender, obesity, history of 
116 snoring or daytime sleepiness, therefore the assessed prevalence might represent an overestimation 
117 of the actual OSA prevalence in the overall PA population because of selection bias. In the HYPNOS 
118 study, among 207 patients with a confirmed diagnosis of PA, the prevalence of OSA was 67.6%[14]. 
119
120 3.Ethnic differences in primary aldosteronism and obstructive sleep apnea prevalence
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121 Whether ethnic differences might affect the risk of both OSA and PA onset has been a matter of 
122 debate. The prevalence of OSA in the general Caucasian population was estimated to be as high as 
123 38% to even more than 90% in selected cohorts[2,22,23] and it was observed to be 64.4% in patients 
124 with PA[14]. The prevalence of PA was found to be 5.9% in the general hypertensive population[12] 
125 and 11.8% in Caucasian patients with OSA[14]. 
126 The SDB risk in Asian patients was reported to be higher than in Caucasians[31]. OSA is more 
127 frequent in Chinese men than in women, although prevalence discrepancies lower along with 
128 age[32,33]. The elevated SDB risk in Asians may be correlated to anatomical factors, such as the 
129 higher frequency of craniofacial skeletal anomalies and the different body fat distribution compared 
130 to Caucasians[31]. Asian patients usually display a greater dietary salt intake than Caucasians, and 
131 this feature, along with an elevated salt-sensitivity of blood pressure, might contribute to hydrosaline 
132 retention and pharyngeal edema[34]. In the HYPNOS study, Chinese patients with PA had a 70% 
133 prevalence of OSA, which was not significantly different compared with Caucasians[14], and resulted 
134 to be similar to that reported in Chinese with essential hypertension[35]. Moreover, aldosterone 
135 positively correlated with apnea-hypopnea index (AHI) in Caucasians with PA, but not in Chinese 
136 patients[14]. Hence, it is reasonable to suppose that the pathophysiology of OSA in Asians might be 
137 related mostly to anthropomorphic predisposing features and high salt intake than to aldosterone-
138 mediated mechanisms.
139 Current evidences suggest that SDB risk is greater among patients of African descent compared to 
140 Caucasians[31,36,37]. SDB predisposition might be correlated to obesity influence and presence of 
141 enlarged upper airway soft tissue in blacks, as well as frequent disadvantageous socio-environmental 
142 conditions and tobacco smoke[31]. Blacks with hypertension tend to have lower plasma renin activity  
143 than whites[38], possibly suggesting a greater frequency of aldosterone-dependent  hypertension [3], 
144 though no differences in PA prevalence have been observed[3,39]. Moreover, blacks tend to be more 
145 salt-sensitive and to display lower responsiveness to angiotensin-converting enzyme inhibitors and 
146 beta-blockers compared to whites[40]. These evidences possibly suggest that aldosterone excess 
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147 might play a relevant role in the pathophysiology of OSA in African-Americans, as supported by a 
148 study reporting a higher prevalence of both OSA and PA compared with Caucasians, Hispanics, and 
149 Asians[28]. 
150
151 The pathophysiological link between aldosterone and OSA
152 1.Obstructive sleep apnea effects on the renin-angiotensin-aldosterone system
153 Several pathophysiological mechanisms relating OSA to  hypertension have been proposed, including 
154 intermittent hypoxia, hypercapnia, intrathoracic negative pressure changes and nocturnal arousals. 
155 Blood pressure increase due to intermittent hypoxic events has been associated to sympathetic 
156 nervous system hyperactivity, enin-angiotensin-aldosterone system (RAAS) overstimulation, 
157 oxidative stress, endothelial dysfunction, endothelin overproduction and pro-inflammatory state[41]. 
158 OSA severity might correlate with aldosterone oversecretion, thus leading to water and sodium 
159 retention, and subsequent rise in blood pressure. Indeed, patients with OSA and RH with normal 
160 plasma renin activity, plasma aldosterone concentration and aldosterone-to-renin ratio displayed a 
161 reduced aldosterone response to saline load along with increasing severity of OSA[42]. 
162 Is aldosterone excess a result of RAAS hypoxia-induced activation in patients with OSA, or does it 
163 represent a contributing factor to OSA pathophysiology? To assess causality of OSA and aldosterone 
164 excess relationship, a number of clinical studies were performed and evaluated the impact of 
165 continuous positive airway pressure (CPAP) treatment on aldosterone levels in patients with OSA. 
166 The results of a meta-analysis of 5 studies indicated minimally yet significantly reduced aldosterone 
167 levels after at least one month of CPAP therapy. Nonetheless, a sub-analysis including only 
168 randomized controlled trials indicated no significant aldosterone changes in the CPAP-treated 
169 patients compared to controls[43]. However, the study performed by Møller et al., showing no 
170 significant decrease of aldosterone levels after CPAP therapy, might be limited by the lack of an 
171 appropriate BMI-matching of enrolled subjects, thus leading to biased results due to obesity influence 
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172 on CPAP effects[44]. Of interest, all included studies were performed in Europe and enrolled patients 
173 were predominantly male, thus ethnicity and gender influence on aldosterone response to CPAP 
174 treatment could not be assessed. 
175 A recent study showed that also short-term CPAP treatment might be able to lower plasmatic 
176 aldosterone and renin levels in moderate-severe OSA patients with type 2 diabetes[45]. Conversely, 
177 a recent randomized controlled trial reported that only optimal CPAP treatment - at least 4 hours per 
178 night during the entire 6-month study period - significantly decreased urinary aldosterone excretion 
179 in RH patients with moderate-severe OSA compared to controls[46]. Another study displayed that 
180 CPAP therapy was able to significantly decrease aldosterone levels and blood pressure in OSA 
181 patients with day-and-night sustained hypertension compared to controls, but not in those with 
182 isolated nocturnal hypertension[47]. Lastly, aldosterone levels were not significantly decreased by 
183 angiotensin receptor-blocker treatment in a cohort of subjects with  hypertension and OSA compared 
184 to those without OSA, while add-on CPAP therapy in the former group tended to lower aldosterone 
185 excess and sympathetic activity. These results support the hypothesis of a subclinical form of 
186 hyperaldosteronism in patients with  hypertension and OSA[48].
187
188 2.Overnight rostral fluid shift as a pathogenetic feature predisposing to obstructive sleep apnea
189 Several evidences support the importance of volume overload and nocturnal rostral fluid shift in the 
190 pathogenesis of OSA. This latter phenomenon is due to redistribution of fluid, accumulated during 
191 daytime in the lower extremities because of gravity, from legs to neck upon lying down at night. Fluid 
192 displacement into neck structures promotes upper respiratory tract soft tissue edema, which in turn 
193 causes airway resistance increase and airflow obstruction[49]. 
194 Targeting fluid overload in hypervolemic patients might be effective to reduce AHI and upper airway 
195 collapsibility in subjects with OSA[49]. A 2-week course of intensified diuretic treatment was 
Page 9 of 20
Georg Thieme Publishers KG, Rüdigerstraße 14, 70469 Stuttgart, Germany































































196 reported to be effective in improving OSA severity in patients with uncontrolled  hypertension and 
197 moderate-severe OSA[50].
198 Aldosterone excess, along with increased dietary sodium intake, leads to fluid overload[1,51]. A 
199 meta-analysis showed that aldosterone and angiotensin II are significantly higher in OSA-affected 
200 patients with hypertension than in normotensive individuals[52]. Therefore, it has been hypothesized 
201 that aldosterone excess might be implicated in volume overload predisposing nocturnal rostral fluid 
202 shift in patients with OSA[51]. Conversely, in a large cross-sectional study plasma aldosterone levels 
203 and plasma renin activity were not significantly different in RH patients with no or mild OSA 
204 compared with patients with moderate-severe OSA[53]. 
205
206 3.Aldosterone blockade and obstructive sleep apnea
207 Several studies documented a positive correlation between aldosterone levels and OSA severity. 
208 Plasma and urinary aldosterone levels significantly correlated with AHI in subjects with RH, but this 
209 correlation was not observed in normotensive individuals nor in patients with treatment-controlled 
210 hypertension of similar age, BMI and OSA severity[46,54]. Nevertheless, a study reported a positive 
211 correlation between aldosterone levels and AHI in patients affected by essential, but not secondary, 
212 RH[29]. Some studies reported that plasma and urinary aldosterone levels positively correlate with 
213 AHI in patients with RH and autonomous aldosterone production. Conversely, no significant 
214 correlation between aldosterone levels and AHI was observed in patients with normal aldosterone 
215 secretion, suggesting that the role of aldosterone in OSA pathogenesis and severity might be relevant 
216 only in subjects displaying a status of aldosterone excess[55,56]. 
217 A number of clinical studies evaluated the effect of aldosterone blockade on airway obstruction. Two 
218 small observational studies reported a significant reduction of AHI after a 2-month treatment with 
219 spironolactone in patients with RH and moderate-severe OSA[57], and a 3-month treatment with 
220 eplerenone in patients with essential RH and OSA, respectively[58]. Likewise, a small randomized 
221 blank-controlled prospective trial showed a significant reduction of OSA severity, blood pressure and 
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222 aldosterone levels in patients affected by RH and moderate-severe OSA after a 3-month 
223 spironolactone therapy on top of preexisting antihypertensive treatment compared to controls[59]. 
224 Furthermore, AHI and neck circumference were reduced by PA medical or surgical therapy in patients 
225 affected by both PA and OSA[30]. 
226 Aldosterone excess might concur to airway obstruction pathogenesis not only by fluid overload-
227 mediated mechanisms, but also through direct impairment and deregulation of central ventilatory-
228 control[41,60]. Nowadays, targeting aldosterone excess has not yet been defined as an effective 
229 treatment for patients with OSA. Notwithstanding, mineralocorticoid receptor-antagonist treatment 
230 should be considered in patients with OSA and RH[41]. 
231
232 4.Primary aldosteronism, obstructive sleep apnea and obesity 
233 The coexistence of high aldosterone levels and OSA might also be attributed to the presence of 
234 common predisposing conditions, such as obesity and metabolic disorder[61]. OSA prevalence is 
235 elevated in individuals affected by obesity or metabolic syndrome, and it is even higher in subjects 
236 with diabetes and morbid obesity[24]. Furthermore, OSA is associated with insulin resistance 
237 independently of concomitant obesity[62] and abnormal glucose metabolism may be attributed to 
238 hypoxemia-induced sympathetic nervous system and RAAS activation[63]. Diabetic neuropathy may 
239 in turn affect central control of respiration promoting sleep apnea development, leading to a vicious 
240 cycle[64]. 
241 Obesity is common in patients with both OSA and RH[1]. Interestingly, aldosterone levels appear to 
242 be higher in patients with OSA and metabolic syndrome compared to those without metabolic 
243 alterations[65]. Several studies observed high aldosterone levels in obese subjects, especially in those 
244 with visceral obesity[66]. Both adolescents and women with obesity displayed significantly higher 
245 aldosterone levels than lean individuals, and weight loss led to significant aldosterone 
246 reduction[67,68]. A recent study demonstrated that urinary aldosterone levels were positively 
247 correlated with BMI in RH patients, especially in men and regardless of ethnicity[69]. Moreover, 
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248 BMI was directly correlated to aldosterone levels in postmenopausal Chinese women with obesity 
249 and hypertension but not in premenopausal women, possibly because of the role of endogenous 
250 estrogens as a regulator of aldosterone secretion before menopause[70].
251 The pathophysiological pathways linking obesity to aldosterone excess still have to be fully 
252 elucidated. Adipose cells are able to produce angiotensinogen and angiotensin II; studies on animal 
253 models showed that angiotensinogen might be released into circulation by adipose tissue and its levels 
254 might correlate with systolic blood pressure[71]. Animal model studies suggested that high 
255 concentrations of fatty acids in portal venous blood of obese individuals might be metabolized by the 
256 liver to oxidized products, such as linoleic acid derivatives, which could stimulate aldosterone 
257 secretion[72]. Adipocyte secretory products, such as adipokines and adipocyte-derived hormones, 
258 may directly stimulate adrenocortical aldosterone secretion, independent of angiotensin II[73]. 
259 Complement-C1q TNF-related protein-1 (CTRP1) was found to be overexpressed in both patients 
260 with obesity and  hypertension,  and to act as an endogenous aldosterone-stimulating factor[74]. Other 
261 adipokines such as tumor necrosis factor-α and interleukin-6 have also been shown to be involved in 
262 aldosterone secretion[75]. In vitro and in vivo studies on animal models showed that the adipocyte-
263 derived anorectic hormone leptin could directly promote aldosterone secretion independently of 
264 potassium, angiotensin II and adrenocorticotropic hormone levels[75,76]. Recent findings suggest 
265 that leptin-mediated pathway leading to hypertension development in patients with obesity might be 
266 mostly dependent to aldosterone oversecretion in women, and predominantly related to hypothalamic 
267 receptor activation and consequent sympathetic nervous system stimulation in men[77]. Interestingly, 
268 the role of obesity in the pathogenesis of aldosterone hypersecretion appeared to be relevant in 
269 patients with BHA, but not with APA[78,79]. These observations suggest that, while aldosterone 
270 overproduction is determined by a hormone-secreting tumor in APA patients, obesity might play an 
271 important role in aldosterone excess by adipokine-driven pathways in subjects with BHA[78,79]. 
272 Vice versa, aldosterone excess might contribute to obesity development through adipose tissue 
273 maturation by means of mineralocorticoid receptor activation, thereby leading to a vicious cycle[80]. 
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274 Higher prevalence of metabolic syndrome and diabetes has been shown in patients with PA compared 
275 with essential hypertension[81]. Insulin secretion might be impaired by either aldosterone-induced 
276 hypokalemia, and direct aldosterone effects resulting in pancreatic beta-cell dysfunction and 
277 apoptosis. Furthermore, hyperaldosteronism-related insulin resistance might be explained by 
278 defective expression of glucose transporter 4, insulin receptor and its related signal transducing 
279 factors in skeletal muscle and adipose tissue, as well as increased hepatic gluconeogenesis and 
280 endothelial remodeling affecting insulin and glucose peripheral delivery[82]. Finally, recent findings 
281 support the coexistence of mild glucocorticoid excess and aldosterone overproduction in PA, 
282 suggesting a role for cortisol-driven pathways in the determination of metabolic risk in a proportion 
283 of patients with PA[83].
284
285 Conclusions
286 Aldosterone excess, OSA and obesity could be interconnected within the context of metabolic 
287 syndrome through vicious cycle pathogenetic mechanisms. Obesity leads to OSA development 
288 through fat deposition within the neck, while OSA could in turn promote obesity. Adipokines released 
289 by visceral fat might induce aldosterone overproduction, which could in turn stimulate fat cell 
290 differentiation. Moreover, aldosterone excess-induced volume overload contributes to OSA 
291 pathogenesis, and intermittent hypoxia might in turn exacerbate RAAS activation. OSA and 
292 hyperaldosteronism might both lead to oxidative stress and inflammation, thus favoring the 
293 production of oxidized lipidic derivatives which could in turn aggravate aldosterone 
294 oversecretion[72]. Furthermore, hyperaldosteronism-related glucose metabolism dysregulation and 
295 diabetes[82] might lead to diabetic neuropathy development, which may consequently affect upper 
296 airway neural reflexes, thus favoring OSA[64]. Consistent with these evidences, OSA is frequently 
297 observed in patients with PA. Conversely, whether PA is more prevalent in patients with OSA 
298 compared with the general population remains controversial.
299
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